Iqvia vs Labcorp
IQV and LH side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IQV and LH compare
Iqvia is the larger company, worth 1.5 times as much as Labcorp ($44.0B against $29.9B).
On earnings, Labcorp is cheaper: it trades at 30.2× trailing earnings, against 33.2× for Iqvia.
Iqvia grew revenue faster over the last twelve months (8.2% versus 6.0% for Labcorp).
Iqvia keeps more of each dollar of sales as profit, with a net margin of 8.1% compared with 6.9% at Labcorp.
Labcorp pays a dividend yielding 0.78%; Iqvia does not pay one.
Labcorp scores higher on the StockData Score (11 against 8 for Iqvia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IQV | LH |
|---|---|---|
| Size and price | ||
| Market cap | $44.0B | $29.9B |
| Share price | $267.33 | $368.16 |
| Change, 1 year | 22.7% | 41.8% |
| Change, 5 years | 8.1% | 34.0% |
| Beta (5Y) | 1.17 | 0.61 |
| Employees | 93K | 71K |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 2 |
| Performance score | 4 (better) | 2 |
| Health score | 0 | 4 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 33.2× | 30.2× (better) |
| P/S | 2.6× | 2.0× (better) |
| P/B | 7.1× | 3.4× (better) |
| EV/EBITDA | 17.2× | 16.0× (better) |
| P/FCF | 20.1× (better) | 23.2× |
| PEG | 2.99 | – |
| FCF yield | 5.0% (better) | 4.3% |
| Fair value | $222.72 | $356.26 |
| Margin of safety | −20.0% | −3.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.2% (better) | 6.0% |
| Revenue growth, 5Y average | 7.5% (better) | −0.04% |
| Net income growth (TTM) | 11.2% | 17.4% (better) |
| EPS growth (TTM) | 16.6% | 19.6% (better) |
| EPS growth, 5Y average | 40.5% (better) | −8.0% |
| Profitability | ||
| Gross margin | 33.0% (better) | 29.0% |
| Operating margin | 13.0% (better) | 10.3% |
| Net margin | 8.1% (better) | 6.9% |
| FCF margin | 12.9% (better) | 8.8% |
| Return on equity | 23.0% (better) | 11.4% |
| Return on invested capital | 9.4% (better) | 8.6% |
| Financial health | ||
| Debt / equity | 2.59 | 0.66 (better) |
| Net debt / EBITDA | 4.11 | 2.53 (better) |
| Interest coverage | 2.9× | 6.5× (better) |
| Current ratio | 0.71 | 1.41 (better) |
| Altman Z-score | 2.20 | 3.55 (better) |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.78% |
| Payout ratio | – | 23.6% |
| Years of dividend growth | – | 0 |
| Buyback yield | 2.6% (better) | 2.3% |
| Shareholder yield | 2.6% | 3.0% (better) |
| Ownership | ||
| Held by institutions | 95.3% | 98.0% |
| Held by insiders | 1.1% | 0.40% |
| Insider net buying, 12 months | −$38.0M | −$11.9M (better) |
| Superinvestors holding | 3 (better) | 1 |
| Short interest, % of float | 2.0% | 3.3% |
Go deeper
- IQV stock overview
- IQV income statement
- IQV valuation and score
- LH stock overview
- LH income statement
- LH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.